LUYE PHARMA (02186) Monthly Return Announcement for February 2026

Bulletin Express03-05

LUYE PHARMA (02186) released its monthly return for equity securities as of 28 February 2026. The authorized share capital remains 10.00 billion ordinary shares with a par value of USD 0.02, amounting to USD 200.00 million in total. No changes in the number of authorized shares were recorded during the month.

The total number of issued shares stands at 3.99 billion. As of the end of February 2026, there were no treasury shares, and no increase or decrease in the issued shares during the month. The public float threshold remains at 25.00%, and the requirement has been confirmed as complied with.

A convertible bond with a principal amount of USD 180.00 million was also disclosed. The subscription price is HKD 4.88 per share, and up to 288.79 million new ordinary shares may be issued if fully converted. No new shares have been issued or transferred from treasury in connection with this instrument during the reporting period.

The company confirms, to the best knowledge and belief, that all necessary authorizations, regulatory requirements, and conditions related to the securities issuance have been fulfilled, including receipt of all funds due, submission of requisite filings, and compliance with all listing rules. The return was submitted by Director Ms. Zhu Yuan Yuan on 05 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169465343?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 17:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169465343","market":"us","top_or_hot":-1,"title":"LUYE PHARMA (02186) Monthly Return Announcement for February 2026","media":"Bulletin Express","content":"<p>LUYE PHARMA (02186) released its monthly return for equity securities as of 28 February 2026. The authorized share capital remains 10.00 billion ordinary shares with a par value of USD 0.02, amounting to USD 200.00 million in total. No changes in the number of authorized shares were recorded during the month.</p>\n<p>The total number of issued shares stands at 3.99 billion. As of the end of February 2026, there were no treasury shares, and no increase or decrease in the issued shares during the month. The public float threshold remains at 25.00%, and the requirement has been confirmed as complied with.</p>\n<p>A convertible bond with a principal amount of USD 180.00 million was also disclosed. The subscription price is HKD 4.88 per share, and up to 288.79 million new ordinary shares may be issued if fully converted. No new shares have been issued or transferred from treasury in connection with this instrument during the reporting period.</p>\n<p>The company confirms, to the best knowledge and belief, that all necessary authorizations, regulatory requirements, and conditions related to the securities issuance have been fulfilled, including receipt of all funds due, submission of requisite filings, and compliance with all listing rules. The return was submitted by Director Ms. Zhu Yuan Yuan on 05 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LUYE PHARMA (02186) Monthly Return Announcement for February 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLUYE PHARMA (02186) Monthly Return Announcement for February 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-05 17:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LUYE PHARMA (02186) released its monthly return for equity securities as of 28 February 2026. The authorized share capital remains 10.00 billion ordinary shares with a par value of USD 0.02, amounting to USD 200.00 million in total. No changes in the number of authorized shares were recorded during the month.</p>\n<p>The total number of issued shares stands at 3.99 billion. As of the end of February 2026, there were no treasury shares, and no increase or decrease in the issued shares during the month. The public float threshold remains at 25.00%, and the requirement has been confirmed as complied with.</p>\n<p>A convertible bond with a principal amount of USD 180.00 million was also disclosed. The subscription price is HKD 4.88 per share, and up to 288.79 million new ordinary shares may be issued if fully converted. No new shares have been issued or transferred from treasury in connection with this instrument during the reporting period.</p>\n<p>The company confirms, to the best knowledge and belief, that all necessary authorizations, regulatory requirements, and conditions related to the securities issuance have been fulfilled, including receipt of all funds due, submission of requisite filings, and compliance with all listing rules. The return was submitted by Director Ms. Zhu Yuan Yuan on 05 March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02186","symbol_name":"绿叶制药","start_time":0,"source_url":"","article_id":"1169465343","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169465343","pubTimestamp":1772703305,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"LUYE PHARMA (02186) released its monthly return for equity securities as of 28 February 2026. The authorized share capital remains 10.00 billion ordinary shares with a par value of USD 0.02,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02186":"绿叶制药"},"translate_title":"绿叶制药(02186)2026年2月月报表公告","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1},"content_text":"LUYE PHARMA (02186) released its monthly return for equity securities as of 28 February 2026. The authorized share capital remains 10.00 billion ordinary shares with a par value of USD 0.02, amounting to USD 200.00 million in total. No changes in the number of authorized shares were recorded during the month.\nThe total number of issued shares stands at 3.99 billion. As of the end of February 2026, there were no treasury shares, and no increase or decrease in the issued shares during the month. The public float threshold remains at 25.00%, and the requirement has been confirmed as complied with.\nA convertible bond with a principal amount of USD 180.00 million was also disclosed. The subscription price is HKD 4.88 per share, and up to 288.79 million new ordinary shares may be issued if fully converted. No new shares have been issued or transferred from treasury in connection with this instrument during the reporting period.\nThe company confirms, to the best knowledge and belief, that all necessary authorizations, regulatory requirements, and conditions related to the securities issuance have been fulfilled, including receipt of all funds due, submission of requisite filings, and compliance with all listing rules. The return was submitted by Director Ms. Zhu Yuan Yuan on 05 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169465343","isCrawlerRequest":true}